These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 22104564)

  • 1. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.
    Chen LT; Chen MF; Li LA; Lee PH; Jeng LB; Lin DY; Wu CC; Mok KT; Chen CL; Lee WC; Chau GY; Chen YS; Lui WY; Hsiao CF; Whang-Peng J; Chen PJ;
    Ann Surg; 2012 Jan; 255(1):8-17. PubMed ID: 22104564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma.
    Lee D; Chung YH; Kim JA; Park WH; Jin YJ; Shim JH; Ryu SH; Jang MK; Yu E; Lee YJ
    Cancer; 2013 Jun; 119(12):2239-46. PubMed ID: 23564564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
    Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
    Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection.
    Tanimoto Y; Tashiro H; Aikata H; Amano H; Oshita A; Kobayashi T; Kuroda S; Tazawa H; Takahashi S; Itamoto T; Chayama K; Ohdan H
    Ann Surg Oncol; 2012 Feb; 19(2):418-25. PubMed ID: 21710324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma.
    Urata Y; Kubo S; Takemura S; Uenishi T; Kodai S; Shinkawa H; Sakae M; Kaneda K; Ohata K; Nozawa A; Suehiro S
    J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):685-96. PubMed ID: 22203455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.
    Lo CM; Liu CL; Chan SC; Lam CM; Poon RT; Ng IO; Fan ST; Wong J
    Ann Surg; 2007 Jun; 245(6):831-42. PubMed ID: 17522506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study.
    Yang T; Lu JH; Zhai J; Lin C; Yang GS; Zhao RH; Shen F; Wu MC
    Eur J Surg Oncol; 2012 Aug; 38(8):683-91. PubMed ID: 22621971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial.
    Sun HC; Tang ZY; Wang L; Qin LX; Ma ZC; Ye QH; Zhang BH; Qian YB; Wu ZQ; Fan J; Zhou XD; Zhou J; Qiu SJ; Shen YF
    J Cancer Res Clin Oncol; 2006 Jul; 132(7):458-65. PubMed ID: 16557381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.
    Hsu YC; Ho HJ; Wu MS; Lin JT; Wu CY
    Hepatology; 2013 Jul; 58(1):150-7. PubMed ID: 23389758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
    Zhang CH; Xu GL; Jia WD; Ge YS
    Int J Cancer; 2009 Jun; 124(12):2982-8. PubMed ID: 19296539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.
    Xia Y; Qiu Y; Li J; Shi L; Wang K; Xi T; Shen F; Yan Z; Wu M
    Ann Surg Oncol; 2010 Dec; 17(12):3137-44. PubMed ID: 20602260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.
    Kuzuya T; Katano Y; Kumada T; Toyoda H; Nakano I; Hirooka Y; Itoh A; Ishigami M; Hayashi K; Honda T; Goto H
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1929-35. PubMed ID: 17914972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival.
    Ishikawa T; Higuchi K; Kubota T; Seki K; Honma T; Yoshida T; Kamimura T
    Hepatogastroenterology; 2012; 59(114):529-32. PubMed ID: 22024226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial.
    Ishizuka M; Kubota K; Nemoto T; Shimoda M; Kato M; Iso Y; Tago K
    Asian J Surg; 2016 Jul; 39(3):149-54. PubMed ID: 26123137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant systemic drug therapy and recurrence of hepatocellular carcinoma following curative resection.
    Zhong Y; Liu B; Deng M; Xu R
    Drug Discov Ther; 2013 Aug; 7(4):164-6. PubMed ID: 24071579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels.
    Miyaguchi S; Watanabe T; Takahashi H; Nakamura M; Saito H; Ishii H
    Hepatogastroenterology; 2002; 49(45):724-9. PubMed ID: 12063979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy after curative treatment for hepatocellular carcinoma.
    Kudo M
    Oncology; 2011; 81 Suppl 1():50-5. PubMed ID: 22212936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.
    Mazzaferro V; Romito R; Schiavo M; Mariani L; Camerini T; Bhoori S; Capussotti L; Calise F; Pellicci R; Belli G; Tagger A; Colombo M; Bonino F; Majno P; Llovet JM;
    Hepatology; 2006 Dec; 44(6):1543-54. PubMed ID: 17133492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation.
    Qi W; Zhang Q; Xu Y; Wang X; Yu F; Zhang Y; Zhao P; Guo H; Zhou C; Wang Z; Sun Y; Liu L; Xuan W; Wang J
    J Viral Hepat; 2020 Apr; 27(4):387-396. PubMed ID: 31755220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Forns index predicts recurrence and death in patients with hepatitis B-related hepatocellular carcinoma after curative resection.
    Choi WM; Lee JH; Ahn H; Cho H; Cho YY; Lee M; Yoo JJ; Cho Y; Lee DH; Lee YB; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS; Kim CY; Lee HS
    Liver Int; 2015 Aug; 35(8):1992-2000. PubMed ID: 25556714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.